174402-32-5
中文名称 | 174402-32-5 |
---|---|
中文同义词 | 化合物 T15200 |
英文名称 | Edotecarin |
英文同义词 | Edotecarin;J 107088;PF 804950;Edotecarin (J 107088);5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 12-β-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- |
CAS号 | 174402-32-5 |
分子式 | C29H28N4O11 |
分子量 | 608.56 |
EINECS号 | |
相关类别 | |
Mol文件 | 174402-32-5.mol |
结构式 |
174402-32-5 性质
熔点 | 330° (dec) |
---|---|
比旋光度 | D23 +117° (c = 0.8 in 1:1 acetonitrile/water) |
沸点 | 1047.5±75.0 °C(Predicted) |
密度 | 1.96±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
形态 | 固体 |
酸度系数(pKa) | 9.61±0.20(Predicted) |
颜色 | 黄至橙色 |
Topoisomerase I 50 nM (IC 50 ) |
Protein Kinase C 160 μM (IC 50 ) |
In the presence of human colon cancer cells labeled with 3 Hthymidine, edotecarin (0.6 μmol/L) increases the formation of DNA-protein complexes in a time-dependent manner.
Edotecarin produces an 83% increase in survival in mice bearing intracranial D-456MG glioma and shows a strong antimetastatic effect. Edotecarin results in tumor growth delays ranging from 10.45 days at the lowest dose (3 mg/kg) to 24.83 days at the highest (100 mg/kg). Combination treatment of edotecarin plus irinotecan improves antitumor activity in vivo compared with either agent alone.